...
首页> 外文期刊>BMC Cancer >miRNA profiling, detection of BRAF V600E mutation and RET-PTC1 translocation in patients from Novosibirsk oblast (Russia) with different types of thyroid tumors
【24h】

miRNA profiling, detection of BRAF V600E mutation and RET-PTC1 translocation in patients from Novosibirsk oblast (Russia) with different types of thyroid tumors

机译:新西伯利亚州(俄罗斯)患有不同类型甲状腺肿瘤的患者的miRNA分析,BRAF V600E突变检测和RET-PTC1易位

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background The postoperative typing of thyroid lesions, which is instrumental in adequate patient treatment, is currently based on histologic examination. However, it depends on pathologist’s qualification and can be difficult in some cases. Numerous studies have shown that molecular markers such as microRNAs and somatic mutations may be useful to assist in these cases, but no consensus exists on the set of markers that is optimal for that purpose. The aim of the study was to discriminate between different thyroid neoplasms by RT-PCR, using a limited set of microRNAs selected from literature. Methods By RT-PCR we evaluated the relative levels of 15 microRNAs (miR-221, ?222, ?146b, ?181b, ?21, ?187, ?199b, ?144, ?192, ?200a, ?200b, ?205, ?141, ?31, ?375) and the presence of BRAF(V600E) mutation and RET-PTC1 translocation in surgically resected lesions from 208 patients from Novosibirsk oblast (Russia) with different types of thyroid neoplasms. Expression of each microRNA was normalized to adjacent non-tumor tissue. Three pieces of lesion tissue from each patient (39 goiters, 41 follicular adenomas, 16 follicular thyroid cancers, 108 papillary thyroid cancers, 4 medullary thyroid cancers) were analyzed independently to take into account method variation. Results The diagnostic classifier based on profiling of 13 microRNAs was proposed, with total estimated accuracy varying from 82.7 to 99?% for different nodule types. Relative expression of six microRNAs (miR-146b, ?21, ?221, ?222, 375, ?199b) appeared significantly different in BRAF(V600E)-positive samples (all classified as papillary thyroid carcinomas) compared to BRAF(V600E)-negative papillary carcinoma samples. Conclusions The results confirm practical feasibility of using molecular markers for typing of thyroid neoplasms and clarification of controversial cases.
机译:背景技术甲状腺病变的术后分型目前在组织学检查的基础上,有助于对患者进行适当的治疗。但是,这取决于病理学家的资格,在某些情况下可能很困难。大量研究表明,分子标记物(例如microRNA和体细胞突变)可能对这些情况有用,但在为此目的最佳的标记物集合上尚无共识。该研究的目的是通过使用有限的选自文献的微小RNA,通过RT-PCR区分不同的甲状腺肿瘤。方法通过RT-PCR我们评估了15种microRNA的相对水平(miR-221,?222,?146b,?181b,?21,?187,?199b,?144,?192,?200a,?200b,?205 ,?141,?31,?375)以及BRAF(V600E)突变和RET-PTC1易位在来自新西伯利亚州(俄罗斯)不同类型甲状腺肿瘤的208例患者的手术切除病变中的存在。每个microRNA的表达被标准化为相邻的非肿瘤组织。独立分析每个患者的三个病变组织(39个甲状腺肿,41个滤泡性腺瘤,16个滤泡性甲状腺癌,108个乳头状甲状腺癌,4个甲状腺髓样癌),以考虑方法差异。结果提出了一种基于13种microRNA分析的诊断分类器,对于不同的结节类型,总的估计准确度从82.7%到99 %%不等。与BRAF(V600E)-相比,BRAF(V600E)阳性样本(均归为乳头状甲状腺癌)中的六个microRNA(miR-146b,?21,?221,?222、375,?199b)的相对表达似乎有显着差异。阴性乳头状癌样品。结论结果证实了使用分子标记物进行甲状腺肿瘤分型和澄清争议病例的实际可行性。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号